Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic

References

• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Picard C, Gaspar HB, Al-Herz W, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96–128.
   PubMed Web of Science ®Google Scholar
• Babaha F, Rezaei N. Primary immunodeficiency diseases in COVID-19 pandemic: a predisposing or protective factor? Am J Med Sci. 2020;S0002-9629(20):30339.
   Google Scholar
• Shaker MS, Oppenheimer J, Grayson M, et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. J Allergy Clin Immunol Pract. 2020;8(5):1477–1488.e5.
   PubMed Web of Science ®Google Scholar
• Meyts I, Bucciol G, Quinti I, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2020;S0091-6749(20):31320–31328.
   Google Scholar
• Ho HE, Mathew S, Peluso M, et al. Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City. J Allergy Clin Immunol Pract. 2020;S2213-2198(20):31102–31108.
   Google Scholar
• Quinti I, Lougaris V, Milito C, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020;146(1):211–213.e4.
   PubMed Web of Science ®Google Scholar
• https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance
   Google Scholar
• Zhang Q. Human genetics of life-threatening influenza pneumonitis. Hum Genet. 2020;139(6–7):941–948.
   PubMed Web of Science ®Google Scholar
• Moens L, Meyts I. Recent human genetic errors of innate immunity leading to increased susceptibility to infection. Curr Opin Immunol. 2020;62:79–90.
   PubMed Web of Science ®Google Scholar
• Pfeuffer S, Pawlowski M, Joos GS, et al. Autoimmunity complicating SARS-CoV- 2 infection in selective IgA-deficiency. Neurol Neuroimmunol Neuroinflamm. 2020;7(6):e881.
   PubMed Web of Science ®Google Scholar
• Guetl K, Moazedi-Fuerst F, Rosskopf K, et al. SARS-CoV-2 positive virus culture 7 weeks after onset of COVID-19 in an immunocompromised patient suffering from X chromosome-linked agammaglobulinemia. J Infect. 2020;S0163-4453(20):30684–30688.
   Google Scholar
• Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383(23):2291–2293.
   PubMed Web of Science ®Google Scholar
• Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183(7):1901–1912.e9.
   PubMed Web of Science ®Google Scholar
• Kemp SA, Collier DA, Datir R, et al. Neutralising antibodies drive spike mediated SARS-CoV-2 evasion. medRxiv. 2020 Dec 29;2020.12.05.20241927. DOI: 10.1101/2020.12.05.20241927.Preprint.
   PubMedGoogle Scholar
• Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585.
   PubMed Web of Science ®Google Scholar
• Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7(3):ofaa102.
   PubMed Web of Science ®Google Scholar
• Quinti I, Mitrevski M. Modulatory effects of antibody replacement therapy to innate and adaptive immune cells. Front Immunol. 2017;8:697.
   PubMed Web of Science ®Google Scholar
• Aljaberi R, Wishah K. Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2020;125(3):349–350.
   PubMed Web of Science ®Google Scholar
• Schwaiger J, Karbiener M, Claudia Aberham C, et al. No SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic. J Infect Dis. 2020;222(12):1960–1964.
   PubMed Web of Science ®Google Scholar
• ESID COVID-19 statement. www.ESID.org
   Google Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470.
   PubMed Web of Science ®Google Scholar
• Pathak EB. Convalescent plasma is ineffective for covid-19. BMJ. 2020;371:m4072.
   PubMedGoogle Scholar
• Murphy MF, Dzik S. COVID-19, plasma, and hypogammaglobulinemia. Blood. 2020;136(20):2245–2246.
   PubMed Web of Science ®Google Scholar
• Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290–2295.
   PubMed Web of Science ®Google Scholar
• Matheu V, Gonzalez-Perez R, Poza-Guedes P, et al. Letter to the editor: support through social networks of e-health in adults with primary immunodeficiencies during COVID-19 pandemic. Telemed J E Health. 2020;26:1438–1439.
   PubMed Web of Science ®Google Scholar
• Pulvirenti F, Cinetto F, Milito C, et al. Health-related quality of life in common variable immunodeficiency italian patients switched to remote assistance during the COVID-19 pandemic. J Allergy Clin Immunol Pract. 2020;8(6):1894–1899.e2.
   PubMed Web of Science ®Google Scholar
• Quinti I, Pulvirenti F, Giannantoni P, et al. Development and initial validation of a questionnaire to measure health-related quality of life of adults with common variable immune deficiency: the CVID_QoL questionnaire. J Allergy Clin Immunol Pract. 2016;4(6):1169–1179.e4.
   PubMed Web of Science ®Google Scholar
• Tabolli S, Giannantoni P, Pulvirenti F, et al. Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies. Front Immunol. 2014;5:605.
   PubMed Web of Science ®Google Scholar
• Searing DA, Dutmer CM, Fleischer DM, et al. A phased approach to resuming suspended allergy/immunology clinical services. J Allergy Clin Immunol Pract. 2020;8(7):2125–2134.
   PubMed Web of Science ®Google Scholar
• Joint statement on the current epidemics of new coronavirus available at www.esid.org
   Google Scholar
• Brough HA, Kalayci O, Sediva A, et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – the 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics. Pediatr Allergy Immunol. 2020;31(5):442–448.
   PubMed Web of Science ®Google Scholar
• Devogelaere J, D’hooghe MB, Vanderhauwaert F, et al. Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis. Neurol Sci. 2020;41(8):1981–1983.
   PubMed Web of Science ®Google Scholar
• Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135(21):1912–1915.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570.
   PubMed Web of Science ®Google Scholar